Drugs /

folfox-7 regimen

Back to Drugs List

Overview

NCI Definition [1]:
A regimen consisting of leucovorin, infusional fluorouracil and oxaliplatin used for the treatment of advanced-stage and metastatic colorectal cancer. This version differs from the original FOLFOX (FOLFOX4) regimen with regards to both the doses and the administration of the three-drug combination.

Clinical Trials

View Clinical Trials for folfox-7 regimen

Folfox-7 regimen has been investigated in 1 clinical trial, of which 1 is open and 0 are closed. Of the trial investigating folfox-7 regimen, 1 is phase 1 (1 open).

Microsatellite Stable (MSS) is the most frequent biomarker inclusion criterion for folfox-7 regimen clinical trials.

Colorectal carcinoma is the most common disease being investigated in folfox-7 regimen clinical trials [2].

Top Biomarker Inclusion Criteria for Open Clinical Trials Investigating Folfox-7 Regimen
This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating folfox-7 regimen and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,956 clinical trials for which biomarker status defines treatment.

Drug Details

NCIT ID [1]:
C63592

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.